Navigation Links
Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Spain
Date:3/29/2017

TEL AVIV, Israel, March 29, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ("Neurim") and Exeltis announced today a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim's new Rx PedPRM in Spain.

Neurim's paediatric prolonged-release Melatonin is an age-appropriate drug targeted to treat sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep medication approved for children.

The collaboration with Exeltis will help increase the accessibility of the new drug to children and their families. "We are delighted to be working with Exeltis and bring this much needed treatment to Spain. Neurim continues to focus on executing its goal of making PedPRM commercially available in all markets," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals.

Alberto Fábregas, Managing Director of Exeltis Healthcare in Spain added, "We will be working hard with Neurim to bring this much needed treatment to these children suffering from insomnia in Spain. We are proud of our cooperation with Neurim that started as licensees of Circadin in Spain. This new agreement will reinforce our specialization in insomnia and our presence in Neurology."

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in Total Sleep Time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals 

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East. The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

About Exeltis 

Exeltis, the branded pharmaceutical division of Chemo Group, combines the knowledge and experience gained by the group in almost forty years with the values of entrepreneurial spirit, diversity and excellence. With a sound positioning in the Women's Health, CNS, Respiratory, Dermatology and Ophthalmology, it has a portfolio of almost 300 medicines and presence in more than 40 countries.

Contact
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (PedPRM) to be Marketed by Biocodex in France
3. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
4. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. Access Pharmaceuticals Reports First Quarter Results
7. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
8. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
9. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
10. Aveo Pharmaceuticals, Inc. Sued by Investor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... TORONTO , May 11, 2017  Thornhill ... ) has been awarded an $8,049,024 USD five-year, ... Defense through the Canadian Commercial Corporation (CCC) ( ... Field Anesthesia Systems to administer general anesthesia to ... environment.  "The US Marine Corps have ...
(Date:5/10/2017)... 2017 CSSi, the global leader in patient ... industry, is proud to announce the launch of its ... features both enriched content and a customized layout that ... company,s already well-established position as the top global patient ... many months of hard work, we are delighted to ...
(Date:5/8/2017)... -- MACRA replaces the outdated sustainable growth rate ... Black Book Research crowdsource-surveyed 8,845 physician practices from February ... for MIPS Compliance Technology is Booming ... or more clinicians seek to buy Merit-Based Incentive Payment ... of the changes, the hunt is on for the ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, ... recipes for Memorial Day entertaining that are sure to satisfy your guests’ flavor ... sliced meats and cheeses featured in these refreshingly balanced recipes are packed with ...
(Date:5/26/2017)... Bradley, Illinois (PRWEB) , ... May 26, 2017 , ... ... , The community, which is located on more than four acres of land at ... their independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors ... its 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, ... , As part of BluSky’s partnership with The Adoption Exchange, BluSky will also ...
(Date:5/24/2017)... Yorba Linda, Ca (PRWEB) , ... May 24, ... ... discriminating between effects and background. Understanind and choosing the most appropriate instruments for ... will prove critical in research finding. This webinar will focus on innovations in ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Dr. Manju R. ... ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the emotional ... offers convenient, clear braces in Cincinnati, OH. Patients no longer need to feel the ...
Breaking Medicine News(10 mins):